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Sunday, June 6, 2010  
 
15:00 – 17:30   Conference check-in (Hospitality Desks 3 & 4) 
 
17:30 – 18:00   Welcoming Remarks and Opening of the Conference  
 
18:00 – 19:00   Keynote  
    Introducing new vaccines 
    David Salisbury 
    Director of Immunization, UK Department of Health 
 
19:00 – 20:00   Welcome Reception 
 






•  Technical Sessions will be held in Ballroom Nayarit, sections 3-5. 
 
•  Poster Sessions will be held in Ballroom Nayarit, sections 1-2. 
 
•  Breakfasts and lunches will be in the Momo NoHana Restaurant and dinners will be in the Sunset 
Garden. 
 
•  The conference banquet on Thursday will be held in Ballroom Nayarit, sections 3-5. 
 
•  Audiotaping, videotaping and photography of presentations are prohibited. 
 
•  Speakers – Please leave at least 5 minutes for questions and discussion. 
 
•  Please do not smoke at any conference functions. 
 
•  Turn your cellular telephones to vibrate or off during technical sessions. 
 
•  Be sure to make any corrections to your name/contact information on the Master  
Participant List or confirm that the listing is correct.  A corrected copy will be sent to all participants 





Monday, June 7, 2010 
 
07:30 – 08:30   Breakfast 
 
08:30 – 10:00   Session I: Vaccine Target Identification & Validation 
    Session Chairs:   
David Weiner, University of Pennsylvania, USA 
Paula Alves, IBET, Portugal 
 
   Antibodies for the prophylaxis and treatment of infection 
Peter Lachmann, Cambridge University, UK  
 
Defining human immune responses by quantitative, integrated single-cell analysis 
J. Christopher Love, Massachusetts Institute of Technology, USA 
 
10:00 – 10:30   Break 
 
10:30 – 11:30   Session I: Vaccine Target Identification & Validation (continued) 
 
Efficacy of a new generation of DNA vaccine encoding retrovirus-based virus-like 
particles to induce both cellular and humoral immune responses and its application to 
HCV 
David Klatzmann, Hôpital Pitié-Salpêtrière; France 
 
    Universal Flu Vaccines: Now more than ever 
    Annie De Groot, EpiVax, Inc., USA 
 
11:30 – 12:30   Session II : Vaccinology 
Session Chairs:  
Annie de Groot, EpiVax, USA 
Kathrin Jansen, Pfizer, USA 
 
Immunization to ameliorate atherosclerotic cardiovascular diseases  
Mark Carvlin, CardioVax, USA 
 
Potent, rapid and cost-effective Influenza vaccines made in e.coli 
Thomas Hofstaetter, Vaxinnate, USA  
 
12:30 – 13:30   Lunch 
 
13:30 – 15:00   Ad hoc sessions, free time 
 
15:00 – 17:00   Session II: Vaccinology (continued) 
 
Iscomatrix™ adjuvant links and adaptive immune responses 
Debbie Drane, CSL Limited, Australia 
 
    Glucan particles as a targeted antigen-adjuvant-sima delivery system 
    Gary Ostroff, University of Massachusetts Medical School, USA 
 
    Advances in conjugate vaccine design and development 
    Robert Hepler,  Merck, USA 
 
 Enhanced DNA vaccines delivered by mid EP induce broadly reactive T cell and B 
 cell responses in nonhuman primates and humans 
 David Weiner,  University of Pennsylvania, USA 
 




Monday, June 7, 2010 (continued) 
 
17:30 – 19:00   Session III: Bioprocess Development in Early Stages   
    Session Chairs:  
 Herve Pinton, Sanofi-Pasteur, France 
 Amine Kamen, National Research Council, Canada 
 
A Microbial Platform for Low-cost VLP Vaccines 
Anton Middelberg, University of Queensland, Australia  
 
Rabies and rotavirus vaccines in Vero cells  
Neuza Maria Frazatti-Gallina, Instituto Butantan, Brazil  
 
Influence of host cell defense during influenza vaccine production in MDCK cells 
Timo Frensing, Max-Planck-Institute, Germany 
 
19:00 – 20:30   Dinner 
 







Tuesday, June 8, 2010 
 
07:30 – 08:30   Breakfast 
 
08:30 – 10:00   Session III: Bioprocess Development in Early Stages (continued) 
 
    Development of recombinant protein based chemical conjugate malaria 
    vaccines targeting the pre-erthrocytic state, transmission blocking, or both 
    David Narum, NIAID, NIH, USA 
 
    Development of inactivated polio vaccine from attenuated sabin strains for 
    clinical studies and technology-transfer purposes 
    Yvonne Thomassen, Netherlands Vaccine Institute, the Netherlands 
 
Clinical development of formulated therapeutic and prophylactic DNA-based vaccines 
Alain Rolland, Vical Incorporated, USA 
 
10:00 – 10:30   Break 
 
10:30 – 12:30   Session IV: Vaccines in Late Stage Development  
    Session Chairs:  
 Manon Cox, Protein Sciences Corp., USA 
 Nathalie Garcon, GlaxoSmithKline, Belgium 
 
    Massively Parallel Sequencing: A new method for detecting adventitious 
    Agents and a new tool in virus discovery 
    David Onions, BioReliance Inc., UK 
 
RTS,S/AS A Malaria vaccine candidate in PHASE III clinical development 
Nathalie Garcon, GlaxoSmithKline, Belgium  
 
Purification process development for a second generation human papillomavirus 
vaccine:  challenges new valencies can pose to a process platform 
Michael Kosinski, Merck, USA 
 
Development and characterization of a new quadrivalent meningococcal conjugate 
vaccine that is immunogenic at all ages  
Francesco Berti, Novartis, Italy  
  
12:30 – 13:30   Lunch 
 
13:30 – 15:30   Ad hoc sessions, free time 
 
15:30 – 16:00   Session IV: Vaccines in Late Stage Development (continued) 
 
 After the license approval: How analytics can keep you in the market 
 Robert Sitrin,  Merck, USA 
 
16:00 – 17:15   Session V: Recently Launched Vaccines  
    Session Chairs:  
George Siber, Genocea Biosciences Inc., USA 
John Aunins, Merck, USA 
  
An inactivated cell culture derived JEV Vaccine (IC51) towards worldwide licensure 
Alex von Gabain, Intercell AG, Austria   
  
Development of a conjugated polysaccharide vaccine that affords expanded 
worldside coverage against pneumococcal disease  






Tuesday, June 8, 2010 (continued) 
 
17:15 – 17:45   Break 
 
17:45 – 19:00   Session V: Recently Launched Vaccines (continued) 
  
Challenges in confronting pandemic influenza using novel adjuvanted vaccines 
Louis Fries, GlaxoSmithKline, USA 
 
    Building process understanding for vaccine manufacturing using data mining 
    Matthew Wiener 
    Merck, USA 
 
19:00 – 20:30   Dinner 
 





Wednesday, June 9, 2010 
 
07:30 – 08:30   Breakfast 
 
08:30 – 10:00   Session VI : Veterinary Vaccines 
    Session Chair: 
 Jules Minke, Merial, USA 
 
Nipah/Hendra: Understanding the links between human and veterinary emerging 
diseases 
Jules Minke, Merial, USA 
 
Enhancing the role of veterinary vaccines in reducing zoonotic disease of  
humans: Linking systems biology with vaccine delivery 
L. Garry Adams, Texas A&M College of Veterinary Medicine, USA 
 
 The challenge of developing new generation vaccines for control and eradication of             
                                                    foot and mouth disease in South America 
Susana Levy, Biogenesis-Bago S.A., Argentina 
 
10:00 – 10:30   Break 
 
10:30 – 11:00                              Process Scale-up and Optimization for Production of High Efficacy Oral Rabies 
 Vaccine 
Amine Kamen, National Research Council, Canada 
 
11:00 – 11:45   Keynote Talk 
    Immunogen Discovery: Past, Present, Future 
Adel Mahmoud, Princeton University, USA 
 
11:45 – 13:15   Posters/Buffet Lunch 
 
13:15 – 15:30   Session VII :  New Technologies 
  Session Chair: 
 Mike Hoare, University College London, UK 
 
 Progress toward a synthetic glycoconjugate vaccine for clinical malaria: Practical 
 synthesis of the GPI carbohydrate antigen 
 A. Stewart Campbell, Ancora Pharmaceuticals, Inc., USA 
 
 CIM Monolith Technology: Enabling Economic Vaccines Production 
 Matjaz Peterka, BIA Separations, Slovenia 
 
 Sphereon® technology for lyophilized vaccines 
 Edwin Kets, Intervet International BV, Netherlands 
 
Scale-up of an intensified process for rAD35 adenovirus production using the  
PER.C6® cell substrate 
Alfred Luitjens, Crucell, Netherlands 
 
SynconTM DNA vaccines for emerging infectious diseases 
Niranjan Sardesai, Inovio Biomedical Corporation, USA 
 
 Large virus vaccine platforms: development of innovative technology for  aseptic 
 chromatography 
 Hans Blom, GE Healthcare Life Sciences, Sweden 
 






Thursday, June 10, 2010 
 
07:30 – 08 :30   Breakfast 
 
08:30 – 11 :00   Session VIII : Technology Challenges in Developing World Market  
Session Chairs:   
Fiona MacLaughlin, Wellcome Trust, UK 
Mahima Datla, Biological E. Limited, India 
 
IVR's Priorities and Activities on Vaccine Research 
Ana Maria Henao-Restrepo, World Health Organization, Switzerland  
 
New vaccine technologies:  Promising advances may save more lives 
John Boslego, PATH, USA  
 
The global manufacture of Polio vaccine in the endgame of eradication 
Phil Minor, NIBSC, UK 
     
 A broadly applicable stabilization technology for vaccine and other complex 
    biological molecules 
    Jeff Drew, Stabilitech Ltd., UK 
 
    Vaccine stabilization – research, commercialization, and impact 
    Ray Cummings, PATH, USA 
 
11:00 – 11:30   Break 
  
11:30 – 12:15   Keynote  
Hilleman Laboratories: A new joint venture between Merck and Co., Inc. and  
Wellcome Trust 
Altaf Lal, MSD Wellcome Trust Hilleman Laboratories, India  
 
12:30 – 13:30   Lunch 
 
13:30 – 16:00   Ad hoc sessions, free time 
 
16:00 – 18:30   Session IX:  Developing World:  Progress in Key Regions 
    Session Chairs:    
 Leda Castilho, Federal Univ. of Rio de Janeiro, Brazil 
Laura Palomares, UNAM, Mexico 
Barry Buckland, BiologicB, USA 
 
Influenza A(H1N1):  Public Health challenge, lessons learned in Mexico 
Pablo Kuri-Morales, Sanofi-Aventis, Mexico  
 
Safety, immunogenicity and efficacy of Quadrivalent Human Papillomavirus (types 6, 
11, 16, 18) L1 virus-like particle vaccine in Latin American women. Monitoring HPV 
vaccination 
Luisa Lina Villa, Ludwig Institute for Cancer Research, Brazil  
 
Innovative therapeutic cancer vaccines in Cuba:  an update 
Luis Enrique Fernandez, Center of Molecular Immunology, Cuba 
 
Manufacturing flu vaccine in Mexico:  A major public health and technology transfer 
challenge 
Roger Vinas, Sanofi Pasteur, Mexico 
 
 
Thursday, June 10, 2010 (continued) 
 
Establishing a platform for spray drying inhalable vaccines in South Africa 
Willem A. Germishuizen 
MEND Group, South Africa 
 






Friday, June 11, 2010 
 






List of Accepted Poster Presentations 
 
1. Rabies virus glycoprotein (RVGP) expression in Drosophila S2 cells and by Semliki Forest 
Virus (SFV). Synthesis and protection studies 
Carlos Augusto Pereira, Instituto Butantan-Laboratório de Imunologia Viral, Brazil 
 
2. EpiMatrix: Tool for accelerated epitope selection and vaccine design 
Matt Ardito, EpiVax, USA 
3. Vaccine cell substrates and adventitious agent testing 
Rebecca Sheets, National Institutes of Allergy & Infectious Diseases, USA 
4. Development of a novel process to produce a human rabies vaccine using Vero cells grown 
on microcarriers 
Héla Kallel, Institut Pasteur de Tunis, Tunisia 
5. From Ascitis to Bioreactor: Anti-Idiotypic cancer vaccine as a case study 
Yoan J. Machando Hernández, Center for Molecular Immunology, Cuba  
6. Assessment of particle concentration and assembly efficiency during the production of 
rotavirus-like particles in insect cells 
Maria Candida M. Mellado, ITQB-UNL/IBET, Portugal 
 
7. Use of VERO suspension cultures for influenza H1N1 virus production 
Marina Etcheverrigaray, Universidad Nacional del Litoral, Argentina 
 
8. Ultra-scale down methodology for rapid prediction of the impact of P. pastoris high cell 
density cell broth quality on recovery performance of recombinant products in a pilot-scale 
centrifuge 
A.G. Lopes, University College London, Department of Biochemical Engineering, UK 
 
9. Production of serotype 6-derived recombinant adeno-associated virus in serum-free 
suspension cultures of HEK 293 cells 
Érica A. Schulze, Federal University of Rio de Janeiro, Brazil 
 
10.  RNA based plasmid selection system for antibiotic-free plasmid DNA vector production 
Aaron E. Carnes, Nature Technology Corporation, USA 
 
11.  Escherichia coli plasmid DNA fermentation: strain and process-specific effects on vector 
yield, quality, and transgene expression 
Aaron E. Carnes, Nature Technology Corporation, USA 
 
12.  Assessing aggregation using transmission electron microscopy 
Clinton S. Potter, NanoImaging Services, Inc., USA 
 
13.  An alternative platform for rapid, high yield, low cost production of vaccine antigens 
George Buchman, Ph.D., Chesapeake PERL, Inc., USA 
 
14.  Fabrication of influenza virus-like particles with M2 fusion proteins 
Suh-Chin Wu, National Tsing Hua University, Taiwan 
 
15.  Recombinant influenza hemagglutinin production in insect cells 
Linda Lua, The University of Queensland, Australia 
 
 
16.  Strategies for the production of a veterinary vaccine based on recombinant rotavirus VP6 
Laura A. Palomares, Universidad Nacional Autónoma de Mexico, Mexico 
 
17.  M Cell targeted delivery for oral vaccination 
Tarik Khan, The University of Texas at Austin, USA 
 
18.  Purification process development of protein subunit based vaccine candidates produced 
using recombinant e. coli expression system 
Davinder Chawla, Sanofi Pasteur, Canada 
 
19.  Characterization of the N-glycosylation profile of recombinant influenza virus hemagglutinin 
produced in the insect-cell baculovirus expression system 
Laura A. Palomares, Universidad Nacional Autónoma de Mexico, Mexico 
 
20.  HEK-293 cells is an efficient platform for large scale manufacturing of influenza vaccines 
Amine Kamen, Biotechnology Research Institute-National Resrarch Council, Canada 
21.  Acceleration of process development using an HPLC method to monitor reovirus type 3 
particles for manufacturing of Reolysin 
Amine Kamen, Biotechnology Research Institute-National Research Council Canada, Canada 
22.  Accelerated process development for production of an adenovirus-vector vaccine against 
Ebola virus 
Amine Kamen, National Research Council-Biotechnology Research Institute, Canada 
23.  Vaccine manufacturing in the new decade: update on application and validation approach of 
single-use technologies 
Annelies Onraedt, PhD, Pall Life Sciences, Switzerland 
24.  Bringing systems biology to vaccine development: Modeling the self-assembly of Rotavirus-
like particles 
António Roldão, ITQB-UNL; IBET, Portugal 
25.  Characterization of vaccines using transmission electron microcopy 
Bridget Carragher, NanoImaging Services, Inc., USA 
26.  Removal of tolerogenic signals from a dendritic cell-targeting antibody 
Constanze A. Weber, EpiVax, Inc, USA 
27.  Cell-based influenza vaccine process development and analysis 
Hans Blom, GE Healthcare Bio-Sciences AB, Sweden 
28.  Process development and large scale manufacture of a multivalent HIV DNA vaccine. 
Henry L Hebel, VGXI Inc, USA 
29.  Development of a simple and high-yielding fed-batch process for the production of influenza 
vaccines 
Jamal Meghrous, Protein Sciences Corporation, USA 
30.  Bench scale production of influenza virus from suspension culture of MDCK-siat7e cells 
Joseph Shiloach, NIDDK/NIH, USA 
31.  Prototype development and pre-clinical immunogenicity analysis of a novel minimally 
invasive electroporation device 
Kate E. Broderick, Inovio Biomedical, USA 
 
32.  Development of protein capsular matrix vaccine (PCMV) technology 
Kevin P Killeen, Matrivax Research & Development Corp., USA 
33.  De-Tolerization of ANTI-DEC-205 for HIV subunit vaccine delivery 
Shannon Pelletier, EpiVax, USA 
34.  T-cell epitope vaccine provides complete protection against lethal vaccinia infection in HLA 
transgenic mouse model 
William Martin, EpiVax, Inc, USA 
35.  Downstream processing of DNA vaccines: Achieving high productivity and purity 
Matjaz Peterka, BIA Separations, Slovenia 
 
36.  Purification platform for influenza viruses 
Matjaz Peterka, BIA Separations, Slovenia 
 
37.  A vaccine prototype using Baculovirus Expression System for the control of Avian influenza 
virus 
Mauricio Realpe, Boehringer-Ingelheim Vetmedica, Mexico  
38.  Strategy for the consistent preparation of sufficient non-viral large vectors for 
biopharmaceutical applications 
Sally Hassan, Department of Biochemical Engineering, University College London, UK 
39.  Genetic stability of Dengue-4 infectious clone viruses propagated in vero cells and MRC-5 
cells: The implication for vaccine development 
Suh-Chin Wu, National Tsing Hua University, Taiwan 
40.  Chimeric virus-like particles for vaccination against microbial infection 
Tania Rivera-Hernández, The University of Queensland, Australia 
 
41.  Enhancing downstream processing of recombinant baculoviruses: The leverage from the 
fundamentals 
Tiago Vicente, IBET/ITQB-UNL, Portugal 
42.  Personalizing immune responses to vaccines, autoantigens, and protein therapeutics: The 
iTEM (individualized T Cell Epitope Measure) tool 
Tobias Cohen, EpiVax, Inc, USA 
43.  Removal of tolerogenic signals from a dendritic cell-targeting antibody 
Shannon Pelletier, EpiVax, Inc, USA 
44.  E. coli high cell density cultivation using Glycerol as carbon source for PspA3 antigenic 
protein production 
A.C.L. Horta, Universidade Federal de São Carlos, Brazil 
45.  Integration of scientific knowledge and the quality requirements 
Daymara González Fuentes, Center of Molecular Immunology, Cuba 
 
 
46.  Understanding the mechanism of aluminum adjuvant-induced degradation of polysaccharide 
conjugate vaccines 
William James Smith, BioProcess Research and Development, Merck Research Laboratories, USA 
 
47.  High cell-density processes in batch mode for plasmid DNA production by a metabolically 
engineered e. coli strain with minimized overflow metabolism  
Alvaro R. Lara, Universidad Autónoma Metropolitana-Cuajimalpa, Mexico 
 
48.  Elevated head space-pressure:  A viable option to increase oxygen transfer and scale-up e. 
coli cultivations for plasmid DNA vaccine production  
Alvaro R. Lara, Universidad Autónoma Metropolitana-Cuajimalpa, Mexico 
 
49.  Poly-methyl vinyl ether-co-maleic anhydride nanoparticles as antigen delivery and activating 
systems  
Carlos Gamazo, University of Navarra, Spain 
 
50.  Design of experiment based Japanese encephalitis virus formaldehyde inactivation 
optimisation for a vero cell derived vaccine 
Michael Hughson, University College London, UK  
 
51.  Effects of IPTG and kanamycin concentrations on plasmid stability and expression of CLPP 
protein of Streptococcus Pneumoniae in Escherichia coli using experimental design  
Ariane Leites Larentis, Bio-Manguinhos / Fiocruz, Brazil 
 
52.  Human cells for prostate cancer vaccine therapy – The impact of centrifugation upon key 
product quality attributes 
Michael Delahaye, University College London, UK 
 
53.  Ultra-scale down studies of human cell bioprocessing for a prostate cancer vaccine therapy 
– The impact of capillary shear 
Juan Pablo Acosta Martinez, University College London, UK 
 
54.  Rapid development of a novel enveloped Chikungunya virus-like particle vaccine for phase I 
clinical production 
Richard M. Schwartz, Vaccine Research Center / NIAID / NIH, USA 
 
55.  Lipid removal strategies to enable chromatography in the purification of virus-like particles 
Claire Burden, University College London, UK 
 
56.  Application of animal-free recombinant bioactive protein supplements to improve the 
performance of cell-based viral vaccine production 
Kenneth Bertram, Novozymes Biopharma AU, Australia 
 
57.  Viral vaccine production at manufacturing scale (1000 M2 surface) into icellis disposable 
fixed-bed reactor 
Jean-Christophe Drugmand, Artelis, Belgium 
 
58.  Influence of glucose and glutamine metabolism  in animal component-free media for the 
production of viruses in vero cells 
Emma Petiot, Laboratoire Réactions et Génie des Procédés – CNRS, France 
 
59.  Development of a multi-dose formulation for Prevnar 13™ 
Lakshmi Khandke, Pfizer, USA 
 
60.  Development of a high throughput plate reduction neutralization test for the detection of 
mumps virus neutralizing antibodies 
Damien Friel, GlaxoSmithKline Biologicals, Belgium 
 
61.  Validation of a Multiplex Luminex ImmunoAssay (MLIA) for assessment of the 
immunogenicity of Bordetella pertussis vaccines 
Damien Friel, GlaxoSmithKline Biologicals, Belgium 
  
 
